Alvogen, a privately owned pharmaceutical company headquartered in the US, was founded in 2009 and employs approximately 570 individuals. The company focuses on developing, manufacturing, and selling generic, brand, over-the-counter brands, and biosimilar products for patients around the world.
Alvogen, a U.S.-based wholly owned subsidiary of Lotus Pharmaceutical Co. Ltd., and biopharmaceutical public benefit corporation Solaxa Inc. entered into a global license agreement on February 23, 2026. This agreement covers the development and commercialization of SLX-100 for spinocerebellar ataxia type 27B (SCA27B) across global markets. Previously, on January 21, Alvogen announced new progress in its acquisition of pharmaceutical portfolios in Vietnam. The company had previously signed an asset purchase agreement to acquire rights to trademarks, drug marketing licenses, and manufacturing supply agreements for five drugs in Vietnam in mid-2025, with four of these drugs slated for official sale in the first quarter of 2026.
Subscribe for full access to Alvogen's products in full detail 
